The Compass approach
At Compass, we take an unbiased approach to drug discovery by leveraging our proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through our StitchMabs™ and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability.
To date, we have drugged over 40 immune targets and generated a diverse pipeline of monoclonal and multispecific therapeutic candidates with potential to transform care for patients with cancer or autoimmune diseases.
We are targeting the immune synapse with a new generation of antibody therapeutics
Director and Co-Founding Member of Cowen Healthcare Investments
Timothy Anderson is a director and co-founding member of Cowen Healthcare Investments, a venture capital firm affiliated with Cowen Inc. Timothy has led investments into, and currently serves as a board member or board observer of, both Compass Therapeutics and Livongo Health. He is also a member of the investment committee of Lagunita Biosciences, a healthcare incubator based in Menlo Park. Prior to co-founding Cowen Healthcare Investments, Timothy was a biotechnology investment banker in Cowen and Company’s healthcare investment banking group.
He earned a B.A. in economics from Bowdoin College.
Partner, F-Prime Capital
Ben Auspitz is a partner at F-Prime Capital and has worked in pharmaceuticals and life-science for over twenty years, both in industry, as a consultant and as an investor.
Most recently before joining F-Prime Capital, he served as therapeutic area head for immuno-inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into phase II clinical studies, and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics and two companies where he was a company founder of Orchard Therapeutics and Dimension Therapeutics.
He currently serves on the board of directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Turnstone Biologics, Compass Therapeutics and Checkmate Pharmaceuticals. Previously, Ben was involved in F-Prime Capital investments in Symbiomix Therapeutics (acquired by Lupin), Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (Nasdaq: BPMC), Coherus Biosciences (Nasdaq: CHRS), REGENXBio (Nasdaq: RGNX), Dimension Therapeutics (Acquired by Ultragenyx) and Ultragenyx (Nasdaq: RARE).
He holds a B.A. from Harvard University.
Phil Ferneau, MBA, J.D.
Managing Director and Co-founder, Borealis Ventures
Phil Ferneau, MBA, J.D., directs Borealis Ventures’ healthcare investing, leveraging 20 years of experience working with early-stage entrepreneurs to commercialize innovation. He currently leads Borealis’ investments in Adimab, Avedro, Avitide, Compass Therapeutics and Vets First Choice. Phil was also responsible for the firm’s prior investments in GlycoFi (acquired by Merck & Co.) and M2S (acquired by AIG Altaris Health Partners). Phil previously served as the founding executive director of the Center for Private Equity and Entrepreneurship at Dartmouth College’s Tuck School of Business. Phil remains an adjunct member of Tuck’s faculty teaching venture capital and entrepreneurship topics. Earlier in private legal practice, he consulted technology startups, Fortune 500 companies and foreign governments on sensitive trade, tax and investment matters.
Phil received an A.B. degree from Dartmouth College, a J.D. from the University of Virginia School of Law and a MBA (with High Distinction) from the Tuck School of Business at Dartmouth.
Carl L. Gordon, Ph.D., CFA
Founding Partner and Co-head of Global Private Equity, OrbiMed Advisors
Carl L. Gordon, Ph.D., CFA, has been a member of our board since Compass’ inception in 2014. Carl is a founding partner and co-head of global private equity at OrbiMed. Carl co-founded OrbiMed Advisors LLC, or OrbiMed, an investment firm focused on the healthcare sector, in 1998 and, since that time, has served as a member and co-head of private equity. Prior to co-founding OrbiMed, Carl was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a fellow at The Rockefeller University from 1993 to 1995.
Carl received a Ph.D. in molecular biology from the Massachusetts Institute of Technology and a B.A. from Harvard College. Carl was included on the Forbes Midas List of top venture capital investors in 2014.
Carl serves on multiple boards of private and publicly traded companies such as Compass Therapeutics, LLC, Good Start Genetics, Adimab, Arsanis, Singulex, TP Therapeutics, Armo Biosciences and Oric.
Thomas J. Schuetz, MD, Ph.D.
Co-founder and Chief Executive Officer, Compass Therapeutics
Thomas J. Schuetz, M.D., Ph.D. has over 20 years of experience in oncology, biopharmaceutical drug development and life science venture investing. He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. As a physician-scientist and serial entrepreneur, he aspired to create an antibody therapeutic company based on novel biology, protein engineering and key medical insights gathered throughout his career. While at OrbiMed, Thomas co-founded Audentes Therapeutics, now a publicly traded biotechnology company where he remains a director. Also at OrbiMed, he was responsible for the investments in Enobia Pharma, Relypsa and Arteaus Therapeutics, and served as a director at each of those companies. Enobia was acquired by Alexion Pharmaceuticals in 2011, Relypsa was acquired by Galencia in 2016 and Arteaus was acquired by Eli Lilly in 2014. Thomas has multiple years of clinical strategy, development and operations experience including roles as chief medical officer of Therion Biologics Corporation, a cancer vaccine company, and as the vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.
Thomas completed his medical training at Massachusetts General Hospital, where he served as the chief medical resident, and completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Thomas holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University. Thomas is board certified in medical oncology.
Stephen Squinto, Ph.D.
Venture Partner, OrbiMed Advisors
Stephen Squinto, Ph.D., is a venture partner with OrbiMed who brings over 25 years of biotechnology industry experience. Stephen was a co-founder of Alexion Pharmaceuticals, Inc. and recently served as its executive vice president and chief global operations officer. Prior to 2013, he was Alexion’s global head of research and development. From 1988 to 1992, Stephen held various positions at Regeneron Pharmaceuticals, Inc. Prior to Regeneron, he held a joint academic position at both the Tulane University and LSU Medical Schools. He is a recipient of numerous honors and awards from academic and professional organizations for his scientific work.
Stephen received his B.A. in chemistry and Ph.D. in biochemistry and biophysics from Loyola University of Chicago.
Managing Partner and Co-founder, Biomatics Capital Partners
Julie Sunderland, MBA, is the co-founder of and a managing partner at Biomatics Capital Partners. Prior to founding Biomatics in 2016, Julie was director of program-related investments for the Bill & Melinda Gates Foundation. In that role, she led the foundation’s $1.5 billion strategic investment pool, funded 50 investments, including 30 in health care, and built a team of 10 investment professionals. Julie also chaired Bill & Melinda Gates Foundation’s investment committee, which reviews all program-related investments. Prior to that role, she advised foundations, development finance institutions and governments on venture capital, SME financing and technical assistance programs.
Julie holds a B.A. from Harvard University, an MBA from Wharton Business School and an M.A. from Johns Hopkins School of Advanced International Studies. She also sits on the board of directors for several of Biomatics’ portfolio companies including Aledade, BlackThorn, eGenesis and Verana Health.
Steven Tregay, Ph.D.
Co-founder and Chairman of the Board, Compass Therapeutics and Founder, FORMA Therapeutics
Steven Tregay, Ph.D., is a co-founder of Compass Therapeutics and has served as its chairman of board since Compass’ inception. Steven also founded Forma Therapeutics and served as its president and chief executive officer from 2008 to 2019. Prior to founding Forma, Steven was a managing director for the $200M Novartis Option Fund. He led the fund’s investments in and served on the board of directors of Forma Therapeutics, Adenosine Therapeutics (acquired by Clinical Data: FRX) and Cequent Pharmaceuticals (acquired by Marina Biotech: MRNA). Prior to joining the venture group of Novartis, he was the executive director and head of strategic alliances-oncology, ophthalmology and technologies at the Novartis Institutes for BioMedical Research. He managed a team who were responsible for identification, negotiation and management of collaborations for the oncology and ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in business development at Array BioPharma and research.
Steven also serves as a board member of LabCentral. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.